Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IGCS 2022 | Combined PD1 and IDO1 inhibiton in patients with clear cell carcinoma of the ovary

Lilian T. Gien • 3 Oct 2022
IGCS 2022 IGCS 2022
Gynecological Cancer Ovarian Cancer Epacadostat Pembrolizumab

Lilian T. Gien, MD, FRCSC, Sunnybrook Health Sciences Centre, Toronto, Canada, discusses the rationale behind evaluating combined PD-1 and IDO1 inhibition in patients with clear cell carcinoma of the ovary. This interview took place at the Annual Global Meeting of the International Gynecologic Cancer Society (IGCS 2022) in New York City, NY.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Lilian T. Gien

3:26
Phase II trial of pembro & epacadostat in patients with recurrent clear cell carcinoma of the ovary
Lilian T. Gien • 3 Oct 2022

Related Videos

0:39
Early diagnosis of ovarian cancer with Pap smears
Sergio Marchini • 8 Apr 2024
0:46
FRa expression and sequencing ADCs in endometrial cancer
Rebecca Porter • 8 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:11
Clonal hematopoiesis mutations in ovarian carcinomas
Rebecca Porter • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals